Use of novel agents, radiotherapy, and allogeneic HCT by era
| . | All patients (N = 342) . | AHCT in 2001-2010 (N = 159) . | AHCT in 2011-2020 (N = 183) . | P value∗ . | Standardized mean difference∗ . |
|---|---|---|---|---|---|
| BV | |||||
| Received at any time point | 120 (35%) | 15 (9%) | 105 (57%) | <.001 | 118.0% |
| Before transplant | 78 (23%) | 0 (0%) | 78 (43%) | <.001 | 121.9% |
| After transplant | 59 (17%) | 15 (9%) | 44 (24%) | .001 | 39.9% |
| Maintenance therapy | 25 (7%) | 0 (0%) | 25 (14%) | <.001 | 56.3% |
| For PD | 34 (10%) | 15 (9%) | 19 (10%) | .911 | 3.2% |
| PD-1 inhibitor | |||||
| Received at any time point | 58 (17%) | 1 (1%) | 57 (31%) | <.001 | 91.9% |
| Before transplant | 38 (11%) | 0 (0%) | 38 (21%) | <.001 | 72.4% |
| After transplant | 20 (6%) | 1 (1%) | 19 (10%) | <.001 | 43.8% |
| Radiotherapy | |||||
| Received at any time point | 175 (51%) | 116 (73%) | 59 (32%) | <.001 | 89.3% |
| Before transplant | 127 (37%) | 85 (53%) | 42 (23%) | <.001 | 66.1% |
| After transplant | 60 (18%) | 40 (25%) | 20 (11%) | .001 | 37.7% |
| Consolidation | 33 (10%) | 24 (15%) | 9 (5%) | .003 | 34.4% |
| For PD | 27 (8%) | 16 (10%) | 11 (6%) | .236 | 14.9% |
| Allogeneic HCT | |||||
| For progression after AHCT | 38 (11%) | 20 (13%) | 18 (10%) | .527 | 8.7% |
| . | All patients (N = 342) . | AHCT in 2001-2010 (N = 159) . | AHCT in 2011-2020 (N = 183) . | P value∗ . | Standardized mean difference∗ . |
|---|---|---|---|---|---|
| BV | |||||
| Received at any time point | 120 (35%) | 15 (9%) | 105 (57%) | <.001 | 118.0% |
| Before transplant | 78 (23%) | 0 (0%) | 78 (43%) | <.001 | 121.9% |
| After transplant | 59 (17%) | 15 (9%) | 44 (24%) | .001 | 39.9% |
| Maintenance therapy | 25 (7%) | 0 (0%) | 25 (14%) | <.001 | 56.3% |
| For PD | 34 (10%) | 15 (9%) | 19 (10%) | .911 | 3.2% |
| PD-1 inhibitor | |||||
| Received at any time point | 58 (17%) | 1 (1%) | 57 (31%) | <.001 | 91.9% |
| Before transplant | 38 (11%) | 0 (0%) | 38 (21%) | <.001 | 72.4% |
| After transplant | 20 (6%) | 1 (1%) | 19 (10%) | <.001 | 43.8% |
| Radiotherapy | |||||
| Received at any time point | 175 (51%) | 116 (73%) | 59 (32%) | <.001 | 89.3% |
| Before transplant | 127 (37%) | 85 (53%) | 42 (23%) | <.001 | 66.1% |
| After transplant | 60 (18%) | 40 (25%) | 20 (11%) | .001 | 37.7% |
| Consolidation | 33 (10%) | 24 (15%) | 9 (5%) | .003 | 34.4% |
| For PD | 27 (8%) | 16 (10%) | 11 (6%) | .236 | 14.9% |
| Allogeneic HCT | |||||
| For progression after AHCT | 38 (11%) | 20 (13%) | 18 (10%) | .527 | 8.7% |
Bold values denote statistical significance at the P < .05 level.
P values and standardized mean difference values indicate a comparison between patients undergoing AHCT in 2001 to 2010 vs 2011 to 2020.